Oncternal Therapeutics (ONCT) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • Thursday
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 04/18/24
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate CancerGlobeNewsWire • 03/15/24
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/07/24
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/07/24
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 02/29/24
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/06/24
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 02/01/24
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 01/08/24
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell LymphomaGlobeNewsWire • 12/26/23
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/09/23
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/02/23
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 10/26/23
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory BoardGlobeNewsWire • 10/25/23
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 10/05/23
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory BoardGlobeNewsWire • 09/07/23
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/10/23
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/10/23
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/03/23
Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate CancerGlobeNewsWire • 08/03/23
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphomaGlobeNewsWire • 06/06/23